ProKidney Corp. Class A Ordinary Shares (PROK) is a publicly traded Healthcare sector company. As of November 18, 2026, PROK trades at $1.06 with a market cap of $229.87M and a P/E ratio of 0.00. PROK moved -4.09% today. Year to date, PROK is -50.70%; over the trailing twelve months it is -53.73%. Its 52-week range spans $0.46 to $7.13. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces PROK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ProKidney Q3 loss more than doubles as R&D costs rise: ProKidney’s third-quarter 2026 net loss available to Class A stockholders more than doubled year over year to $35.59 million, while revenue fell 20% to $174,000 and R&D expenses rose 52% to $40.85 million. It had $141.9 million in cash and marketable securities at September 30 and expects full PROACT 1 enrollment in Q1 2027, with eGFR-slope results in Q2 2027.
| Metric | Value |
|---|---|
| Price | $1.06 |
| Market Cap | $229.87M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.13 |
| 52-Week Low | $0.46 |
| Volume | 1.57M |
| Avg Volume | 0 |
| Revenue (TTM) | $818.00K |
| Net Income | $-165.75M |
| Gross Margin | 0.00% |
3 analysts cover PROK: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.